DeepCyte Launches DeeTox Atlas for AI Toxicology

DeepCyte launched DeeTox Atlas™, which it describes as a single cell metabolomic reference atlas of drug toxicity mechanisms, the company announced in a press release. Pilot programs with global pharmaceutical companies are set to begin in the coming months.

The atlas is built from two independent single cell metabolomics perturbation studies. It covers about 100 toxicant compounds, 300,000 cells, about 500 metabolites per cell, and more than 3,000 single cell measurements per compound across six biological replicates.

Each compound is mapped to a four level hierarchy of toxicity mechanisms tied to Adverse Outcome Pathways. DeepCyte trains a foundation model on the atlas to predict toxicity mechanisms for compounds it has not measured.

The company also named Mona Lakkis as Senior Vice President of Partnerships. Lakkis previously served as Senior Vice President and General Manager at Owkin and will lead enterprise commercialization as DeepCyte advances pilots with three of the top 20 pharmaceutical companies.